Aliases & Classifications for Polyneuropathy

Summaries for Polyneuropathy

Disease Ontology : 12 A peripheral system disease that is characterized by is damage affecting peripheral nerves (peripheral neuropathy) in roughly the same areas on both sides of the body, featuring weakness, numbness, pins-and-needles, and burning pain.

MalaCards based summary : Polyneuropathy, also known as polyneuropathies, is related to chronic inflammatory demyelinating polyneuropathy and amyloidosis, hereditary, transthyretin-related, and has symptoms including neuralgia An important gene associated with Polyneuropathy is GDAP1 (Ganglioside Induced Differentiation Associated Protein 1), and among its related pathways/superpathways are Guidance Cues and Growth Cone Motility and Neural Crest Differentiation. The drugs Imipramine and Pregabalin have been mentioned in the context of this disorder. Affiliated tissues include liver, skin and testes, and related phenotypes are Decreased viability and Decreased viability

Wikipedia : 76 Polyneuropathy (poly- + neuro- + -pathy) is damage or disease affecting peripheral nerves (peripheral... more...

Related Diseases for Polyneuropathy

Diseases in the Polyneuropathy family:

Polyneuropathy Due to Drug Chronic Polyneuropathy

Diseases related to Polyneuropathy via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 629)
# Related Disease Score Top Affiliating Genes
1 chronic inflammatory demyelinating polyneuropathy 34.1 IFNA2 TTR
2 amyloidosis, hereditary, transthyretin-related 33.6 APOA1 GSN TTR
3 demyelinating polyneuropathy 33.6 MAG PMP22 TTR
4 polyneuropathy, hearing loss, ataxia, retinitis pigmentosa, and cataract 33.6 ABHD12 MBP PNPLA6
5 amyloidosis, finnish type 32.8 GSN TTR
6 guillain-barre syndrome 32.7 MBP MPZ PMP22
7 neuropathy, hereditary, with liability to pressure palsies 32.7 GDAP1 MPZ PMP22
8 hypertrophic neuropathy of dejerine-sottas 32.5 GDAP1 MPZ PMP22
9 charcot-marie-tooth disease, demyelinating, type 1b 32.2 MPZ PMP22
10 neuropathy 31.0 GDAP1 MPZ MT-ATP6 PMP22 PNPLA6 POLG
11 amyloidosis 30.8 APOA1 GSN TTR
12 neuropathy, congenital hypomyelinating or amyelinating, autosomal recessive 30.6 GDAP1 MPZ PMP22
13 tooth disease 30.3 GDAP1 MPZ PMP22
14 charcot-marie-tooth disease, demyelinating, type 1f 30.2 MPZ PMP22
15 charcot-marie-tooth disease, axonal, type 2d 30.2 MPZ PMP22
16 charcot-marie-tooth disease, x-linked dominant, 1 30.2 MPZ PMP22
17 charcot-marie-tooth disease, demyelinating, type 1c 30.2 MPZ PMP22
18 charcot-marie-tooth disease 30.1 GDAP1 MAG MBP MPZ MT-ATP6 PMP22
19 charcot-marie-tooth disease, axonal, type 2b 30.1 MPZ PMP22
20 foot drop 30.1 MPZ PMP22
21 hereditary amyloidosis 30.1 APOA1 GSN TTR
22 roussy-levy hereditary areflexic dystasia 30.0 MPZ PMP22
23 charcot-marie-tooth disease, demyelinating, type 1a 30.0 GDAP1 MPZ PMP22
24 charcot-marie-tooth disease and deafness 30.0 GDAP1 MPZ PMP22
25 charcot-marie-tooth disease, type 4a 29.9 GDAP1 TUBB3
26 neuropathy - hereditary 29.9 MPZ PMP22
27 charcot-marie-tooth disease, axonal, type 2e 29.9 GDAP1 MPZ PMP22
28 optic neuritis 29.8 MAG MBP MPZ
29 motor peripheral neuropathy 29.8 MPZ PMP22
30 neuritis 29.7 MAG MBP MPZ PMP22
31 axonal neuropathy 29.6 GDAP1 PMP22 POLG
32 polyradiculoneuropathy 29.6 MAG MBP MPZ PMP22
33 sensory peripheral neuropathy 29.5 GDAP1 MAG MPZ PMP22
34 facial paralysis 29.4 GSN TUBB3
35 peripheral nervous system disease 29.3 AKR1B1 GDAP1 MAG MBP MPZ PMP22
36 hemolytic anemia, cd59-mediated, with or without immune-mediated polyneuropathy 12.4
37 diabetic polyneuropathy 12.4
38 critical illness polyneuropathy 12.3
39 polyendocrine-polyneuropathy syndrome 12.3
40 ataxia and polyneuropathy, adult-onset 12.2
41 polyneuropathy-intellectual disability-acromicria-premature menopause syndrome 12.2
42 subacute inflammatory demyelinating polyneuropathy 12.1
43 paraneoplastic polyneuropathy 12.1
44 aplasia of extensor muscles of fingers, unilateral, with generalized polyneuropathy 12.1
45 chronic polyneuropathy 12.1
46 charcot-marie-tooth disease, x-linked recessive, 5 12.1
47 polyneuropathy due to drug 12.0
48 axonal polyneuropathy associated with igg/igm/iga monoclonal gammopathy 12.0
49 polyneuropathy associated with igm monoclonal gammapathy with anti-mag 12.0
50 guillain-barre syndrome, familial 12.0

Graphical network of the top 20 diseases related to Polyneuropathy:



Diseases related to Polyneuropathy

Symptoms & Phenotypes for Polyneuropathy

UMLS symptoms related to Polyneuropathy:


neuralgia

GenomeRNAi Phenotypes related to Polyneuropathy according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00055-A-2 10.1 GSN
2 Decreased viability GR00240-S-1 10.1 CD59 TUBB3
3 Decreased viability GR00381-A-1 10.1 MPZ RBP4
4 Decreased viability GR00381-A-2 10.1 RBP4
5 Decreased viability GR00381-A-3 10.1 MPZ RBP4
6 Decreased viability GR00402-S-2 10.1 ABHD12 AKR1B1 APOA1 ARSA CD59 DMXL2
7 no effect GR00402-S-1 9.62 ABHD12 AKR1B1 APOA1 ARSA CD59 DMXL2

MGI Mouse Phenotypes related to Polyneuropathy:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.1 APOA1 CD59 GDAP1 GSN MBP MPZ
2 homeostasis/metabolism MP:0005376 10.09 ABHD12 AKR1B1 APOA1 ARSA CD59 DMXL2
3 behavior/neurological MP:0005386 10.07 ABHD12 AKR1B1 ARSA DMXL2 GDAP1 MAG
4 nervous system MP:0003631 9.77 ABHD12 ARSA DMXL2 GDAP1 GSN MAG
5 hearing/vestibular/ear MP:0005377 9.73 ABHD12 ARSA MAG MBP PMP22 POLG
6 reproductive system MP:0005389 9.23 CD59 DMXL2 GSN MBP MPZ PMP22

Drugs & Therapeutics for Polyneuropathy

Drugs for Polyneuropathy (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 341)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Imipramine Approved Phase 4 50-49-7 3696
2
Pregabalin Approved, Illicit, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 148553-50-8 5486971
3
Lidocaine Approved, Vet_approved Phase 4,Phase 2,Not Applicable 137-58-6 3676
4
Lenalidomide Approved Phase 4,Phase 2,Phase 1 191732-72-6 216326
5 Piracetam Approved, Investigational Phase 4,Phase 2 7491-74-9
6
Citalopram Approved Phase 4 59729-33-8 2771
7
Cilostazol Approved, Investigational Phase 4 73963-72-1 2754
8
Norepinephrine Approved Phase 4,Phase 2 51-41-2 439260
9
Dopamine Approved Phase 4,Phase 3,Phase 2 51-61-6, 62-31-7 681
10
Mexiletine Approved, Investigational Phase 4,Phase 2 31828-71-4 4178
11
Nortriptyline Approved Phase 4 72-69-5 4543
12
Capsaicin Approved Phase 4,Phase 2,Phase 3 404-86-4 1548943
13
Acetylcholine Approved Phase 4,Phase 2,Phase 3,Not Applicable,Early Phase 1 51-84-3 187
14
Carbamazepine Approved, Investigational Phase 4 298-46-4 2554
15
Oxcarbazepine Approved Phase 4 28721-07-5 34312
16
alemtuzumab Approved, Investigational Phase 4,Phase 2 216503-57-0
17
Ranolazine Approved, Investigational Phase 4 142387-99-3, 95635-55-5 56959
18
Folic Acid Approved, Nutraceutical, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1 59-30-3 6037
19 Etiracetam Investigational Phase 4,Phase 2 33996-58-6
20 Antidepressive Agents Phase 4,Phase 2
21 Central Nervous System Depressants Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
22 Neurotransmitter Uptake Inhibitors Phase 4,Phase 2
23 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
24 Psychotropic Drugs Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
25 calcium channel blockers Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
26 Neurotransmitter Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
27 Anti-Anxiety Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
28 Adrenergic Agents Phase 4,Phase 3,Phase 2
29 Analgesics Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
30 Calcium, Dietary Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
31 Antidepressive Agents, Tricyclic Phase 4
32 Anticonvulsants Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
33 Tranquilizing Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
34 Rho(D) Immune Globulin Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
35 Immunoglobulins Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
36 gamma-Globulins Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
37 Immunoglobulins, Intravenous Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
38 Antibodies Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
39 Immunologic Factors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
40 Protective Agents Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1
41 Nootropic Agents Phase 4,Phase 2,Phase 3
42 Autonomic Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
43 Cholinergic Agents Phase 4,Phase 3,Phase 2,Not Applicable,Early Phase 1
44 Diuretics, Potassium Sparing Phase 4,Phase 2,Not Applicable
45 Sodium Channel Blockers Phase 4,Phase 2,Not Applicable
46 Anti-Arrhythmia Agents Phase 4,Phase 2,Not Applicable
47 Folate Phase 4,Phase 2,Phase 3,Phase 1
48 Vitamin B9 Phase 4,Phase 2,Phase 3,Phase 1
49 Micronutrients Phase 4,Phase 2,Phase 3,Phase 1
50 Thioctic Acid Phase 4,Phase 2,Phase 3

Interventional clinical trials:

(show top 50) (show all 390)
# Name Status NCT ID Phase Drugs
1 Imipramine and Pregabalin Combination in Painful Polyneuropathy Unknown status NCT01047488 Phase 4 Imipramine;Pregabalin;Imipramine, pregabalin;Placebo
2 Muscular Electrostimulation of the Sedated and Mechanically Ventilated Critically Ill Patient. Analysis of the Effect on Acquired Muscular Weakness and Its Clinical Consequences. Unknown status NCT02033057 Phase 4
3 Evaluation of the Impact of Training on Outcome Measures in Subjects With Painful Diabetic Neuropathy Unknown status NCT01770964 Phase 4 Pregabalin;placebo
4 IVIg for Demyelination in Diabetes Mellitus Unknown status NCT02372149 Phase 4 10% intravenous immunoglobulin (IVIg);0.9% sodium chloride
5 Effects of Pregabalin on Mechanical Hyperalgesia Unknown status NCT00310583 Phase 4 Pregabalin
6 Levetiracetam for Painful Polyneuropathy Completed NCT00286260 Phase 4 levetiracetam
7 Escitalopram as a Treatment for Pain in Polyneuropathy Completed NCT00162968 Phase 4 escitalopram
8 Asian Study on Cilostazol Effectivity in Neuropathies of Diabetes Mellitus Type 2-A Pilot Study in the Philippines Completed NCT01076478 Phase 4 Cilostazol
9 Patient Assisted Intervention for Neuropathy: Comparison of Treatment in Real Life Situations Completed NCT02260388 Phase 4 Nortriptyline;Duloxetine;Pregabalin;Mexiletine
10 A Study to Compare QUTENZA With Pregabalin for the Treatment of Peripheral Neuropathic Pain (PNP) After 8 Weeks of Treatment Completed NCT01713426 Phase 4 Qutenza;Pregabalin
11 Alpha Lipoic Acid for Treatment of Diabetic Neuropathy Completed NCT02439879 Phase 4 Alpha lipoic acid
12 Botulinum Toxin in Peripheral Neuropathic Pain Completed NCT01251211 Phase 4 botulinum toxin type A
13 Oxcarbazepine for the Treatment of Chronic Peripheral Neuropathic Pain Completed NCT01302275 Phase 4 Oxcarbazepine
14 Lidoderm® (Lidocaine Patch 5%) in Diabetic and Idiopathic Neuropathy Completed NCT00903851 Phase 4 Lidoderm
15 Study To Evaluate The Safety And Efficacy Of Lenalidomide For Refractory Cutaneous Lupus Completed NCT01408199 Phase 4 Lenalidomide
16 MP Diagnostics HTLV Blot 2.4 Post-Market Clinical Study Completed NCT03226119 Phase 4
17 Duloxetine in Patients With Diabetic in Peripheral Neuropathic Pain With or Without Co-morbid Major Depressive Disorder Completed NCT00844194 Phase 4 Duloxetine 60 mg QD;Duloxetine 60 mg QD;Duloxetine 30 mg QD;Duloxetine 30 mg QD;Duloxetine 90 mg QD;Duloxetine 90 mg QD;Duloxetine 60 mg QD;Duloxetine 60 mg QD;Duloxetine 120 mg QD;Duloxetine 30 mg QD;Duloxetine 30 mg QD;Duloxetine 120 mg QD
18 Effect of Pulsing Electrical Fields on Lower Extremity Diabetic Neuropathy: A Pilot, Open-Label Study Completed NCT00614341 Phase 4
19 Postoperative Alpha Lipoic Acid in the Carpal Tunnel Syndrome: a Randomized Controlled Trial. Completed NCT01895621 Phase 4
20 Single vs. Multiple Privigen Dose Regimens in Pediatric CIDP Not yet recruiting NCT03684018 Phase 4
21 Study of Ranexa in Patients With Coronary Artery Disease and Painful Polyneuropathy Terminated NCT00832572 Phase 4 Ranolazine;Placebo
22 Efficacy, Safety, Tolerability and Pharmacokinetics of Concomitant Administration of Tramadol With Duloxetine or Pregabalin Withdrawn NCT01116531 Phase 4 Tramadol;Duloxetine;Pregabalin
23 Alemtuzumab in Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIPD) Withdrawn NCT01757574 Phase 4 Alemtuzumab infusion
24 Lidocaine and Triamcinolone vs Saline Trigger Point Injection for Treatment of Chronic Abdominal Wall Pain Withdrawn NCT02748395 Phase 4 Triamcinolone;Lidocaine
25 Efficacy and Safety Study of Thioctacid Oral Tablets 600mg to Treat Chinese Diabetic Patients With Distal Symmetric Polyneuropathy Unknown status NCT01224353 Phase 2, Phase 3 lipoic acid
26 Neuromuscular Electrical Stimulation for Intensive Care Unit-acquired Weakness Assessment Unknown status NCT02706587 Phase 3
27 Role of Anabolic Steroids on Intensive Care Unit-Acquired Weakness Unknown status NCT03038919 Phase 2, Phase 3 Testosterone cypionate
28 Effects of Benfotiamine on Intraepidermal Nerve Fiber Density (IENFD) Unknown status NCT01868191 Phase 3 Benfotiamine;Placebo for benfotiamine
29 Treadmill, Stretching and Proprioceptive Exercise (TreSPE) Rehabilitation Program for Charcot−Marie−Tooth Neuropathy Type 1A (CMT1A) Unknown status NCT01289704 Phase 2, Phase 3
30 Phase III Clinical Trial of NPB-01maintenance Therapy in Patients With Chronic Inflammatory Demyelinating Polyneuropathy. Completed NCT01824251 Phase 3 NPB-01
31 Actovegin® Versus Placebo in Patients With Diabetic Polyneuropathy (AV-007-IM) Completed NCT00483730 Phase 3 Deproteinised hemoderivative of calf blood (Actovegin)
32 RIMAG Study: Trial of Rituximab Versus Placebo in Polyneuropathy Associated With Anti-MAG IgM Monoclonal Gammopathy Completed NCT00259974 Phase 3 Rituximab
33 Assessment of Efficacy and Safety of Thioctic Acid in the Oral Treatment of Diabetic Polyneuropathy (Stage 1 or 2) Completed NCT00977483 Phase 3 Thioctic Acid;Placebo
34 Evaluating the Efficacy and Safety of Oral Ranirestat (40 and 80 mg) in Mild to Moderate Diabetic Sensorimotor Polyneuropathy Completed NCT00927914 Phase 2, Phase 3 Ranirestat;Placebo
35 Study of Efficacy and Safety of Privigen in Subjects With Chronic Inflammatory Demyelinating Polyneuropathy Completed NCT01184846 Phase 3
36 Efficacy and Safety of Inotersen in Familial Amyloid Polyneuropathy Completed NCT01737398 Phase 2, Phase 3 Inotersen;Placebo
37 The Effect Of Tafamidis For The Transthyretin Amyloid Polyneuropathy Patients With V30M Or Non-V30M Transthyretin Completed NCT01435655 Phase 3 tafamidis
38 Randomized Open-label Trial to Compare Efficacy and Tolerance of Corticosteroids and IVIg Completed NCT01349270 Phase 3 Immunoglobulin perfusion;Prednisone
39 Extension Study of Maintenance Treatment With Subcutaneous Immunoglobulin (IgPro20) for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Completed NCT02027701 Phase 3
40 An Extension of Study Fx-005 Evaluating Long-Term Safety And Clinical Outcomes Of Fx-1006A In Patients With Transthyretin Amyloid Polyneuropathy Completed NCT00791492 Phase 2, Phase 3 Fx-1006A
41 Neuropathic Pain Management Completed NCT01263132 Phase 3 F0434;Gabapentin
42 Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) and Treatment With Subcutaneous Immunoglobulin (IgPro20) Completed NCT01545076 Phase 3
43 Safety and Efficacy Study of Fx-1006A in Patients With Familial Amyloidosis Completed NCT00409175 Phase 2, Phase 3 Fx-1006A;Placebo
44 Safety and Efficacy of AS-3201 in the Treatment of Diabetic Sensorimotor Polyneuropathy Completed NCT00101426 Phase 3 ranirestat, (AS-3201)
45 Immune Globulin Intravenous (IGIV) For Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Completed NCT00220740 Phase 3 Immune Globulin IV (Human), 10% Caprylate/Chromatography Purified;Albumin (Human) 25%, United States Pharmacopeia (USP)
46 Efficacy and Safety Study of Topical Capsaicin in Painful Diabetic Neuropathy Completed NCT00993070 Phase 2, Phase 3 Capsaicin;placebo
47 The Effect of Diflunisal on Familial Amyloidosis Completed NCT00294671 Phase 2, Phase 3 diflunisal
48 Assessment of Efficacy and Safety of Thioctic Acid in the Oral Treatment of Symptomatic Diabetic Neuropathy (SYDNEY 2) Completed NCT00328601 Phase 3 Thioctic Acid
49 Phase III Randomized, Double-Blind, Placebo-Controlled Study of 3,4-Diaminopyridine for Demyelinating Polyneuropathy Completed NCT00004939 Phase 3 ,4-diaminopyridine
50 Phase III Randomized, Double-Blind, Placebo-Controlled Study of Intravenous Immune Globulin for Chronic Inflammatory Demyelinating Polyneuropathy Completed NCT00004772 Phase 3 Immune globulin

Search NIH Clinical Center for Polyneuropathy

Cochrane evidence based reviews: polyneuropathies

Genetic Tests for Polyneuropathy

Genetic tests related to Polyneuropathy:

# Genetic test Affiliating Genes
1 Polyneuropathy 29

Anatomical Context for Polyneuropathy

MalaCards organs/tissues related to Polyneuropathy:

41
Liver, Skin, Testes, Spinal Cord, Heart, T Cells, Bone

Publications for Polyneuropathy

Articles related to Polyneuropathy:

(show top 50) (show all 2973)
# Title Authors Year
1
Concomitant myasthenia gravis, myositis, myocarditis and polyneuropathy, induced by immune-checkpoint inhibitors: A life-threatening continuum of neuromuscular and cardiac toxicity. ( 30533536 )
2019
2
Assessment of autonomic innervation of the foot in familial amyloid polyneuropathy. ( 30102818 )
2019
3
Inflammatory demyelinating polyneuropathy versus leptomeningeal disease following Ipilimumab. ( 29382383 )
2018
4
Lenalidomide-Induced Ischemic Cerebrovascular Disease in Polyneuropathy, Organomegaly, Endocrinopathy, Monoclonal Gammopathy, and Skin Changes Syndrome. ( 29395638 )
2018
5
Is Regenerative Medicine Ready for Prime Time in Diabetic Polyneuropathy? ( 29383511 )
2018
6
Corneal confocal microscopy for identification of diabetic sensorimotor polyneuropathy: a pooled multinational consortium study. ( 29869146 )
2018
7
Acute mitochondrial myopathy with respiratory insufficiency and motor axonal polyneuropathy. ( 28969510 )
2018
8
Neurophysiological study of critical illness polyneuropathy and myopathy in mechanically ventilated children; additional aspects in paediatric critical illness comorbidities. ( 29604150 )
2018
9
Diagnosis and management of transthyretin familial amyloid polyneuropathy in Japan: red-flag symptom clusters and treatment algorithm. ( 29343286 )
2018
10
Chronic inflammatory demyelinating polyneuropathy misdiagnosis: A clinical more than electrophysiogical problem? ( 29406592 )
2018
11
IgPro20, the Polyneuropathy and Treatment with Hizentra<sup>Ar</sup> study (PATH), and the treatment of chronic inflammatory demyelinating polyradiculoneuropathy with subcutaneous IgG. ( 29764262 )
2018
12
Onset of fulminant type 1 diabetes mellitus under immunotolerance status after long-term therapy for chronic inflammatory demyelinating polyneuropathy. ( 29905029 )
2018
13
Cerebrospinal Fluid Cytokine Expression Profile in Multiple Sclerosis and Chronic Inflammatory Demyelinating Polyneuropathy. ( 29182448 )
2018
14
Clinical spectrum and quality of life in patients with chronic polyneuropathy: A cross-sectional study. ( 29687564 )
2018
15
Octagam<sup>Ar</sup> for chronic inflammatory demyelinating polyneuropathy: results from three observational studies. ( 29517417 )
2018
16
Nocebo in chronic inflammatory demyelinating polyneuropathy; a systematic review and meta-analysis of placebo-controlled clinical trials. ( 29627036 )
2018
17
Specific symptoms may discriminate between fibromyalgia patients with vs without objective test evidence of small-fiber polyneuropathy. ( 29430562 )
2018
18
A novel paraneoplastic syndrome with acquired lipodystrophy and chronic inflammatory demyelinating polyneuropathy in an adolescent male with craniopharyngioma. ( 29455190 )
2018
19
Vestibular impairment in chronic inflammatory demyelinating polyneuropathy. ( 29260355 )
2018
20
Sensory nerve degeneration in a mouse model mimicking early manifestations of familial amyloid polyneuropathy due to transthyretin Ala97Ser. ( 29423915 )
2018
21
Difference in normal limit values of nerve conduction parameters between Westerner and Japanese people may need to be considered when diagnosing diabetic polyneuropathy using a Point-of-Care Sural Nerve Conduction Device(NC-stat<sup>a98</sup>/DPNCheck<sup>a8c</sup>). ( 29430866 )
2018
22
Sonographic assessment of carpal tunnel syndrome in diabetic patients with and without polyneuropathy. ( 29901629 )
2018
23
A brain-based pain facilitation mechanism contributes to painful diabetic polyneuropathy. ( 29346515 )
2018
24
Heterozygosity for CMT Type 4 Predicts a Severe Vincristine-induced Polyneuropathy Phenotype: A Case Report and Review of Literature. ( 29877907 )
2018
25
Elevated serum levels of endothelin-1 in patients with chronic inflammatory demyelinating polyneuropathy. ( 29137897 )
2018
26
Increased Prevalence of Polyneuropathy inA Parkinson's Disease Patients: AnA Observational Study. ( 29154292 )
2018
27
Standing postural reaction to visual and proprioceptive stimulation in chronic acquired demyelinating polyneuropathy. ( 29313871 )
2018
28
Corticosteroids in chronic inflammatory demyelinating polyneuropathy : A retrospective, multicentre study, comparing efficacy and safety of daily prednisolone, pulsed dexamethasone, and pulsed intravenous methylprednisolone. ( 29968199 )
2018
29
CD59 deficiency presenting as polyneuropathy and Moyamoya syndrome with endothelial abnormalities of small brain vessels. ( 29843966 )
2018
30
Laboratory Abnormalities in Polyneuropathy and Electrophysiological Correlations. ( 29433597 )
2018
31
The value of electrochemical skin conductance measurement using SudoscanAr in the assessment of patients with familial amyloid polyneuropathy. ( 29883834 )
2018
32
Differences between acute-onset chronic inflammatory demyelinating polyneuropathy and acute inflammatory demyelinating polyneuropathy in adult patients. ( 29603827 )
2018
33
IVIg for apparently autoimmune small-fiber polyneuropathy: first analysis of efficacy and safety. ( 29403541 )
2018
34
Assessment of vestibular-evoked myogenic potentials and video head impulse test in type 2 diabetes mellitus patients with or without polyneuropathy. ( 29330601 )
2018
35
Transthyretin amyloid polyneuropathies mimicking a demyelinating polyneuropathy. ( 29907605 )
2018
36
FIBROMYALGIA AND SMALL FIBER POLYNEUROPATHY: WHAT'S IN A NAME? ( 29938813 )
2018
37
A chemometric approach for characterization of serum transthyretin in familial amyloidotic polyneuropathy type I (FAP-I) by electrospray ionization-ion mobility mass spectrometry. ( 29426546 )
2018
38
Impaired thiol-disulphide homeostasis in patients with axonal polyneuropathy. ( 29359643 )
2018
39
Risk Factors for Incident Diabetic Polyneuropathy in a Cohort With Screen-Detected Type 2 Diabetes Followed for 13 Years: ADDITION-Denmark. ( 29487078 )
2018
40
Subcutaneous IgG for chronic inflammatory demyelinating polyneuropathy. ( 29122522 )
2018
41
Neurofascin and Compact Myelin Antigen-Specific T Cell Response Pattern in Chronic Inflammatory Demyelinating Polyneuropathy Subtypes. ( 29615965 )
2018
42
Elevated leukocyte count in cerebrospinal fluid of patients with chronic inflammatory demyelinating polyneuropathy. ( 29341326 )
2018
43
Aldose reductase inhibitor ranirestat significantly improves nerve conduction velocity in diabetic polyneuropathy: a randomized double-blind placebo-controlled study in Japan. ( 29975462 )
2018
44
Long-Term Spinal Cord Stimulation Alleviates Mechanical Hypersensitivity and Increases Peripheral Cutaneous Blood Perfusion in Experimental Painful Diabetic Polyneuropathy. ( 29522270 )
2018
45
Possible Combined Central and Peripheral Demyelination Presenting as Optic Neuritis, Cervical Myelitis, and Demyelinating Polyneuropathy with Marked Nerve Hypertrophy. ( 29540658 )
2018
46
Bilateral facial nerve palsies secondary to chronic inflammatory demyelinating polyneuropathy following adalimumab treatment. ( 29179036 )
2018
47
Diabetic polyneuropathy, deep white matter lesions, and carotid atherosclerosis: is there any association? ( 29063451 )
2018
48
The ulnar ratio as a sensitive and specific marker of acute inflammatory demyelinating polyneuropathy. ( 29940481 )
2018
49
Drug-induced hypersensitivity syndrome followed by chronic inflammatory demyelinating polyneuropathy. ( 29671897 )
2018
50
Characterization of the Nile Grass Rat as a Unique Model for Type 2 Diabetic Polyneuropathy. ( 29718319 )
2018

Variations for Polyneuropathy

ClinVar genetic disease variations for Polyneuropathy:

6
# Gene Variation Type Significance SNP ID Assembly Location
1 GDAP1 NM_018972.2(GDAP1): c.715C> T (p.Leu239Phe) single nucleotide variant Pathogenic rs104894080 GRCh37 Chromosome 8, 75276240: 75276240
2 GDAP1 NM_018972.2(GDAP1): c.715C> T (p.Leu239Phe) single nucleotide variant Pathogenic rs104894080 GRCh38 Chromosome 8, 74364005: 74364005
3 ERCC5 NM_000123.3(ERCC5): c.2929_2930delCT (p.Leu977Valfs) deletion Likely pathogenic rs1057518813 GRCh37 Chromosome 13, 103525658: 103525659
4 ERCC5 NM_000123.3(ERCC5): c.2929_2930delCT (p.Leu977Valfs) deletion Likely pathogenic rs1057518813 GRCh38 Chromosome 13, 102873308: 102873309
5 SMC1A NM_006306.3(SMC1A): c.2981A> G (p.Gln994Arg) single nucleotide variant Uncertain significance rs781817923 GRCh37 Chromosome X, 53410167: 53410167
6 SMC1A NM_006306.3(SMC1A): c.2981A> G (p.Gln994Arg) single nucleotide variant Uncertain significance rs781817923 GRCh38 Chromosome X, 53383246: 53383246

Expression for Polyneuropathy

Search GEO for disease gene expression data for Polyneuropathy.

Pathways for Polyneuropathy

Pathways related to Polyneuropathy according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 11.4 GDAP1 GSN MAG
2 11.14 MBP MPZ PMP22
3
Show member pathways
10.54 RBP4 TTR
4 9.53 MAG MBP

GO Terms for Polyneuropathy

Cellular components related to Polyneuropathy according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular exosome GO:0070062 9.92 AKR1B1 APOA1 ARSA CD59 GSN RBP4
2 protein-containing complex GO:0032991 9.77 GSN MBP POLG RBP4 TTR
3 extracellular space GO:0005615 9.61 AKR1B1 APOA1 ARSA CD59 DMXL2 GSN
4 myelin sheath GO:0043209 9.46 GSN MAG MBP MPZ
5 Schmidt-Lanterman incisure GO:0043220 9.26 AKR1B1 MAG
6 compact myelin GO:0043218 8.8 MAG MBP PMP22

Biological processes related to Polyneuropathy according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 response to ethanol GO:0045471 9.58 ARSA GSN RBP4
2 negative regulation of viral entry into host cell GO:0046597 9.43 GSN IFNA2
3 response to hyperoxia GO:0055093 9.37 MT-ATP6 POLG
4 glycerophospholipid catabolic process GO:0046475 9.32 ABHD12 PNPLA6
5 cell-cell adhesion via plasma-membrane adhesion molecules GO:0098742 9.26 MAG MPZ
6 negative regulation of heterotypic cell-cell adhesion GO:0034115 9.16 APOA1 MBP
7 retinoid metabolic process GO:0001523 9.13 APOA1 RBP4 TTR
8 myelination GO:0042552 8.8 MBP MPZ PMP22

Molecular functions related to Polyneuropathy according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 lysophospholipase activity GO:0004622 8.62 ABHD12 PNPLA6

Sources for Polyneuropathy

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....